Navigation Links
Musical duets lock brains as well as rhythms
Date:11/29/2012

Researchers from the Max Planck Institute for Human Development in Berlin have shown that synchronization emerges between brains when making music together, and even when musicians play different voices. In a study published November 29th in Frontiers in Neuroscience, Johanna Snger and her team used electrodes to record the brain waves of guitarists while they played different voices of the same duet. The results point to brain synchronicity that cannot be explained away by similitudes in external stimulation but can be attributed to a more profound interpersonal coordination.

Scientists working with Ulman Lindenberger at the Max Planck Institute in Berlin already discovered synchronous brain activity between musicians playing the same piece in 2009. The current study goes one step further by examining the brain activity of guitar players performing a piece of music with two different parts. Their aim was to find out whether musicians' brains would synchronize if the two guitarists were not playing exactly the same notes, but instead played different voices of the same song.

To test their hypothesis, the psychologists arranged 32 experienced guitarists in duet pairs, and recorded electrical activity in different brain regions of each musician. They were then asked to play a sequence from the "Sonata in G Major" by Christian Gottlieb Scheidler a total of 60 times, and the duet partners were given slightly different tasks: each musician had to play a different voice, and one of the two was responsible for ensuring that they started at the same time and held the same tempo. Thus, one person took the lead and the other followed.

The duet's brain activities showed coordinated brain oscillations, even when playing different voices of the same duet. Called phase coherence, this synchronous activity suggests a direct neural basis for interpersonal coordination.

"When people coordinate their own actions, small networks between brain regions are
'/>"/>

Contact: Johanna Snger
saenger@mpib-berlin.mpg.de
49-306-950-4201
Frontiers
Source:Eurekalert  

Page: 1 2

Related biology news :

1. New musical pacifier helps premature babies get healthy
2. Primates brains make visual maps using triangular grids
3. Preemies brains reap long-term benefits from Kangaroo Mother Care
4. Mice with big brains provide insight into brain regeneration and developmental disorders
5. University of Alberta led research may have discovered how memories are encoded in our brains
6. Brandeis scientists win prestigious prize for circadian rhythms research
7. Circadian rhythms have profound influence on metabolic output, UCI study reveals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Musical duets lock brains as well as rhythms
(Date:3/12/2015)... 2015 IriTech, a leading iris based identity ... Texas Instruments Design Network, announced today that the Chief ... IriShield USB MK2120U device during a launching event of ... The iris scanner is manufactured by ... India through its Indian partner, ...
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... of the "Access Control Market by Product, Application ... 2020" report to their offering. , ... expected to reach $10.4 billion by 2020, with an ... market report covers the products types such as contact ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... people usually don,t die from a heart attack. But the ... succumb to congestive heart failure, the most common cause of ... hope for achieving what the body can,t do: mending broken ... built a scaffold that supports the growth and integration of ...
... -- A microscopic gene may play a gigantic role when ... to one Kansas State University research team. The team ... Disintegrin and Metalloprotease family, or ADAM family, and its role ... is a good guy or a bad guy in breast ...
... against cancerous tumors, radiation therapy often harms healthy tissue as ... of Tel Aviv University,s Department of Biomedical Engineering is developing ... and minimal damage to surrounding tissue. His innovative ... uses heat to kill the tumor cells but leaves ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3K-State research team investigates mutated gene's role in breast cancer 2A 'magnetic' solution to identify and kill tumors 2
(Date:3/30/2015)... 30, 2015 US-Australian drug discovery company, Novogen ... CanTx, Inc., and Yale University, on March 27 released ... was presented as an oral presentation by Professor ... to the 62 nd Annual Scientific Meeting of ... Francisco, CA. In both in ...
(Date:3/30/2015)... BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... Europe and the United States and plenary talks by ... for SPIE Optics + Optoelectronics next month ... 700 technical presentations in 17 conferences alongside a two-day ... optics and photonics , the event will run 13-16 ...
(Date:3/29/2015)... Texas , March 29, 2015  Caris ... studies in which Caris Molecular Intelligence®, the company,s ... similarities and differences between several rare and difficult ... strategies that have the potential to improve patient ... Session B at the Society of Gynecologic Oncology ...
(Date:3/27/2015)... 27, 2015 The consumption of compound ... the recession and high prices in 2008. However, the ... and keeps on gaining momentum now. , To date, ... more than 100,000 thousand tonnes. No considerable growth was ... global capacity rocketed during 2012-2013, registering 11% growth as ...
Breaking Biology Technology:Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3
... , SUNNYVALE, Calif., July 23 FlowCardia, ... the treatment of chronic total occlusions (CTOs), today announced the appointment ... previously held the position of Executive VP, Sales and Marketing at ... including the last 2 years at FlowCardia. , ...
... , , , ... with Moderate to Severe Post-Operative Pain , ... QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation ... and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV ...
... , ST. LOUIS, July 23 Sigma-Aldrich Corporation ... Technology company, reported second quarter 2009 diluted EPS of $0.68 compared ... six months ended June 30, 2009, reported diluted EPS was $1.36, ... months of 2008. Excluding the negative impact of currency, EPS ...
Cached Biology Technology:FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer 2QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy 2QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 2Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 3Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 4Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 5Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 6Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 7Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 8Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 9Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 10Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 11Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 12Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 13Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 14Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 15Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 16Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65. 17
Request Info...
CoverWell imaging chamber gasket with adhesive, one chamber, 20 mm diameter, 1.0 mm deep *set of 40* Cell Biology Imaging Tools and Accessories Microscope Slide Accessories...
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
... as 10X concentrated solutions. REact Buffer SetConsists of ... REact buffers and one 250 microl vial of ... ml vials of REact 1 Buffer four 1 ... ml vials of REact 3 Buffer and four ...
Biology Products: